Dr. Scott Alan Celinski, MD

Dr. Celinski practices at Texas Oncology PA in Dallas, Texas.

Dr. Celinski's NPI, 1982872453, was assigned on February 18, 2008. Dr. Celinski graduated from Baylor College Of Medicine in 2002. Dr. Celinski's Texas license number on file is N6835.

Dr. Celinski's primary practice is Texas Oncology PA, at 3410 Worth St, Dallas, TX 75246 in Dallas County. The practice phone is (972) 997-8000.

Dr. Celinski's primary practice is Texas Oncology PA in Dallas, Texas. Dr. Celinski is also affiliated with Baylor University Medical Center. The medical group on file is HealthTexas Provider Network (HTPN). Dmand AI also links Dr. Celinski to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Celinski practices, 3 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Celinski's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Celinski is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Celinski's licenses on file in 4 states: Texas, District of Columbia, Pennsylvania and Virginia.

Dmand AI lists abdominal adhesion surgery and colon removal among the conditions Dr. Celinski treats.

CMS data shows 353 Medicare services from Dr. Celinski across 11 procedure codes in 2024, for 185 Medicare patients. Medicare paid $23,611 for them.

CMS counts 185 Medicare patients who saw Dr. Celinski in 2024. The largest group is 65 to 74, with 98 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.49, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Celinski's median patient age at 67, with 65% women.

In 2024, Dr. Celinski wrote 145 Medicare Part D claims for 59 patients. 77% of them were for generic drugs. CMS names the drug for 91 of them, across 3 drugs with 11 or more claims each, at $108,724 in total drug cost.

Dr. Celinski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Celinski as offering telehealth.

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 15 papers to Dr. Celinski, published from 2011 to 2023. 2019 was the busiest year, with 3. The most frequent topics are Amino Acid Sequence, DNA-Binding Proteins and Leucine Zippers. Dr. Celinski has published most often in Proc (Bayl Univ Med Cent). Dr. Celinski's most frequent co-authors are James Shun Dah Hu, MD, Christine Susan Landry, MD and John T. Preskitt, MD.

Dmand AI links Dr. Celinski to 3 clinical trials. Conditions studied include Pancreatic Neoplasms and Pancreatic Diseases. Baylor Research Institute sponsors the most, 3.

CMS Open Payments shows 10 general payments to Dr. Celinski from 4 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $450.

Dmand AI lists 1 award for Dr. Celinski.

Dr. Celinski graduated from Baylor College Of Medicine in 2002. Dr. Celinski is a member of ACS and ASCO.

Dr. Celinski is in network with 22 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.